Alkermes plc (Nasdaq: ALKS) announced the initiation of a phase 1 clinical study of the company’s immuno-oncology drug candidate, ALKS ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE